Femasys Inc. Common Stock (FEMY) — Analysis Summary
Femasys Inc. Common Stock (FEMY) has a market cap of $11.20M with year-over-year revenue growth of +40.8%. Net margin stands at -812.3%. The stock trades at a P/E ratio of -0.9.
Key Takeaways
- Revenue changed +40.8% year-over-year
- Net margin of -812.3%
- P/E ratio of -0.9
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, FEMY posted revenue growth of +40.8% and trades at a P/E of -0.9.
Femasys Inc. Common Stock (FEMY)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -10.2x — earnings do not cover interest payments
Operating margin at -687.9% — severe operating losses
Net margin at -500.0% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
54
Headquarters
SUWANEE, GA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.